1 Experiences and attitudes towards Menstrual Suppression among Women with Bacterial

2 vaginosis Randomised to Continuous Use of NuvaRing in Kenya

3 Authors

- 4 Edinah Casmir MA¹, Njeri Wairimu BA¹, Catherine Kiptinness MPH¹, Lynda Oluoch MPH,
- 5 MBChB¹, Stephen Gakuo Maina MSc², Kristina Wilbekin Walker³, Nelly Mugo MBChB,
- 6 MMed^{1,4}, Jeanne Marrazzo MD, MPH⁵, Kenneth Ngure PhD, MSc, MPH⁶
- 7

8 Author Affiliation

- ⁹ ¹Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
- 10 ²African Population and Health Research Center
- ¹¹ ³Department of Epidemiology, School of Public Health, University of Alabama at Birmingham,
- 12 Birmingham, AL, USA
- ⁴Department of Global Health, University of Washington, Seattle, WA, USA
- ⁵Department of Infectious Diseases, University of Alabama at Birmingham Heersink School of
 Medicine, Birmingham, AL, USA
- ⁶School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi,
 Kenya
- 18 Corresponding Author
- 19 Edinah Casmir_ Research Scientist
- 20 Kenya Medical Research Institute
- 21 Tel: +254711944654
- 22 Email: ednyab@gmail.com/ ecasmir@kemri.go.ke/ ecasmir@pipsthika.org
- 23 <u>Orchid ID: 0000-0001-9568-721X</u>

¹ | Page

25 Abstract

26	Background: The contraceptive vaginal ring (NuvaRing), one of the Multipurpose Prevention
27	Technologies (MPT) products, is effective in preventing unintended pregnancies and may
28	contribute to reducing the frequency of Bacterial Vaginosis (BV), which is a risk factor for
29	HIV acquisition, transmission, and shedding among women. NuvaRing may cause irregular
30	menstruation, including menstrual suppression, which may influence women's decision on
31	product choice, use, and acceptability. In this prospective cohort study, we assessed women's
32	experiences with menstruation suppression following continued NuvaRing use.
33	
34	Methods: A total of 18 in-depth interviews were conducted using a semi-structured interview
35	guide among purposively selected women with BV in Thika, Kenya, aged 18-40 years, who
36	used NuvaRing continuously. All women received counseling on possibility of menstrual
37	suppression following continuous NuvaRing use. Audio recordings were transcribed verbatim
38	and thematically analyzed.
38 39	and thematically analyzed.
	Results: Participants who expected and were aware that menstrual suppression was a possible
39	
39 40	Results: Participants who expected and were aware that menstrual suppression was a possible
39 40 41	Results: Participants who expected and were aware that menstrual suppression was a possible side effect of Nuvaring accepted its benefits, and expressed acceptance and desire to continue
39 40 41 42	Results: Participants who expected and were aware that menstrual suppression was a possible side effect of Nuvaring accepted its benefits, and expressed acceptance and desire to continue using NuvaRing. Participants who had not anticipated menstrual suppression expressed anxiety
 39 40 41 42 43 	Results: Participants who expected and were aware that menstrual suppression was a possible side effect of Nuvaring accepted its benefits, and expressed acceptance and desire to continue using NuvaRing. Participants who had not anticipated menstrual suppression expressed anxiety and fear, with some expressing desire to continue using NuvaRing but worried about
 39 40 41 42 43 44 	Results: Participants who expected and were aware that menstrual suppression was a possible side effect of Nuvaring accepted its benefits, and expressed acceptance and desire to continue using NuvaRing. Participants who had not anticipated menstrual suppression expressed anxiety and fear, with some expressing desire to continue using NuvaRing but worried about unintended negative consequences. The ability to perform daily activities uninterrupted,

48	unintended pregnancy. As a result, they frequented medical facilities for health check-ups and
49	pregnancy tests, and some used combined oral contraceptives to induce menses.
50	
51	Conclusion: Understanding perceptions regarding menstrual suppression is crucial in offering
52	targeted and comprehensive counseling to improve women's understanding of menstruation
53	suppression to influence acceptance and use of NuvaRing. Additionally, improved male
54	involvement in reproductive health concerns and women's autonomy in discussing
55	reproductive health issues with partners is essential.
56	
57	Key Words
58	Menstrual suppression; experiences; attitudes; Contraceptive vaginal ring (CRV); Bacterial
59	vaginosis; NuvaRing; Multipurpose Prevention Technologies

61 Introduction

Women of reproductive age in sub-Saharan Africa (SSA) are faced with the double burden of 62 risk for human immunodeficiency virus (HIV) and unintended pregnancy (1,2). Although a 63 decline in new Human Immunodeficiency Virus (HIV) infections has been observed in this 64 region, women account for more than half (51%) of the HIV burden (1,2) with an estimation 65 66 prevalence of 6.6 % in Kenya which is twice that of men (3.1%) (3.4). This is despite the efforts to improve access to the HIV prevention technologies including pre-exposure prophylaxis (PrEP) 67 and condoms among others (1,5). Reasons for lack and/or low uptake of these interventions 68 69 could be associated with stigma, gendered differences in relationships, lack of female-initiated products, low PrEP coverage, and non-adherence with the use of the available prevention 70 technologies. This situation calls for preventive technologies that could address the double 71 72 burden and the challenges in using the products that are currently available (1,6-9). Multipurpose Prevention Technologies (MPT) addresses the double burden of unintended 73 74 pregnancy and sexually transmitted infections (STI) including HIV in reproductive age women 75 (10). In SSA, bacterial vaginosis (BV) is found in more than 55% of women and is a substantial 76 risk factor for HIV acquisition in, transmission to male partners from, HIV infected women, and 77 genital HIV shedding (11,12). Pregnancy is also an independent risk factor of HIV transmission and acquisition and therefore contraception provides biomedical prevention for women with or at 78 79 risk of HIV (10). The contraceptive vaginal ring (NuvaRing), a hormonal contraceptive vaginal 80 ring containing estrogen and progesterone, recently introduced in Kenya, is effective in preventing pregnancy and may contribute to reducing frequency of BV, and HIV shedding 81

82 among HIV infected women, however, it may result in irregular menstruation including

83 menstrual suppression (6,7).

Menstruation is a normal physiological process that is surrounded by a variety of socio-cultural 84 beliefs that may influence women's decision-making on use of products that affect their 85 menstrual bleeding, such as long or short duration, heavy or light, or suppression of menses (13– 86 17). Menstruation is perceived as a process of cleansing the body by getting out the menstrual 87 blood that is perceived to be 'dirty blood' (13-15,17). Literature shows that menstruation 88 89 impacts on women's daily activities, including work, school, and sexual relationships among others. Although menstruation suppression is somehow acceptable (13,18–20), literature shows 90 that menstrual suppression is perceived to cause a build-up of "dirty" or "blocked" blood, which 91 92 is in turn perceived as causing blood clots, fibroids, emotional disturbances, weight gain,

93 infertility, or death (13,14,17,18).

94 A variety of social-cultural factors may influence menstrual suppression perceptions (14–16). Literature indicates little understanding and recognition of how social, cultural, interpersonal, 95 and individual beliefs, values, and perceptions influence menstrual suppression perception and 96 97 its influences on acceptability, willingness to use, and actual use of biomedical interventions 98 (8,13–16,18,20). Understanding the end-user experiences and how they may influence 99 acceptability and willingness to use novel prevention technologies is essential among 100 researchers, policymakers, and service providers for informing decisions about product 101 development and formulation, roll-out, counselling, awareness, and marketing (6-8,13,19,21). 102 Therefore, it is crucial to understand how end-user experiences may affect acceptance and 103 willingness to use NuvaRing, depending on its impact on hormonal changes that may ultimately cause changes in the women's menstrual cycle, resulting in menses suppression. This paper 104 explores how women's experiences, perceptions and attitudes of menstrual suppression with 105 106 continuous use of the NuvaRing may influence its acceptability and use in Kenyan women.

107 Methods

108 Study population and setting

109 A qualitative sub-study was conducted between May 2017 to February 2018, nested within a 110 randomised clinical trial that aimed to determine the effects of the NuvaRing on the vaginal microbiome and BV, HIV shedding and local immunity (clinicalTrials.gov Identifier: 111 112 NCT02445989). This trial, conducted at Thika Partners Study Clinic (Partners in Health Research and Development), in Central Kenya, enrolled 121 women aged 18-40 years with BV 113 114 based on clinical criteria (Amsel's criteria). Women were either HIV-infected and not on antiretroviral therapy (ART) according to Kenya ART guidelines or HIV-uninfected and, not 115 intending to become pregnant during the study period, did not have any contraindications to 116 hormonal contraceptive, specifically to contraceptive vaginal ring as well as capable of providing 117 written informed consent. The participants were enrolled between April 2016 and November 118 119 2017 and randomized to continuous or cyclical NuvaRing use, with a 6-month follow-up period. 120 However, those who accepted the alternate hormonal contraception offered at month 7 were followed up for an additional month. Women were counselled on pregnancy prevention, and, 121 HIV prevention if HIV-uninfected; condoms were provided to the participants throughout the 122 123 study. Since menstrual suppression is likely to occur among continuous users of NuvaRing, women randomised in the continuous use arm and who had used the ring for at least 2 months 124 were interviewed to understand their experiences and attitudes towards menstrual suppression 125 that might influence its acceptability and use among Kenyan women. 126

127 Data collection

A total of 18 in-depth interviews (IDIs) were conducted using semi-structured interview guides
aimed at identifying participants' experiences with continuous use of NuvaRing. Topics included

menstrual experiences over time, changes in menstruation before and after use of NuvaRing and
participants thoughts about the changes, as well as perceptions towards menstrual suppression
with NuvaRing use. Women who consented to qualitative interviews at enrolment and were
willing to be interviewed to share their menstrual experiences over time with continuous use of
the NuvaRing were approached to participate in the interviews. Interviews were conducted in
English and Kiswahili, and audio-recorded by trained behavioural scientists in the participants'
preferred language at a private location.

137 Data analysis

138 Audio recordings were transcribed verbatim, with Kiswahili Interviews simultaneously translated

to English as needed. All transcripts were reviewed by behavioural scientists to ensure

140 consistency and clarity, then uploaded to Dedoose Version 9.0.17 (Los Angeles, CA, USA), a

141 web-based analysis application tool, for coding. The research team developed themes that guided

142 development of a codebook through inductive and deductive approaches. Data were coded by

143 two behavioural scientists after inter-coder agreement was reached. Output for specific themes

144 (excerpts) were used to describe the study findings.

145 Ethical considerations

Ethical approval was obtained from Kenya Medical Research Institute's Scientific Review
committee and Ethics Review Board (SERU). All participants gave written informed consent to
participate in the study. Women and men who were unable to read or write and expressed
interest in the study were offered to have the consent read to them with a witness present. All

- study materials were labelled with a unique identifier to prevent participants from being
- 151 individually recognized by staff.

152 **Results**

Findings from this study revealed that most participants experienced menstrual suppression with 153 continuous use of NuvaRing. Some participants experienced suppression before and after using 154 NuvaRing, while others experienced suppression only after NuvaRing use. A few participants 155 experienced suppression before joining the study but did not experience it with continuous 156 157 NuvaRing use, while others had never experienced suppression in their lifetime. Participants who experienced suppression before joining the study associated it to the side effects of using 158 contraception such as depo, implants and combined oral contraceptives. Some attributed it to 159 160 changes in climate, diet and stress. Most participants reported that some women experience menstrual suppression naturally in their 161 162 lifetime, while others intentionally suppressed their menses using combined oral contraception. Some women intentionally induce their menses by taking combined contraceptives, blue (dye), 163 and drinking concentrated tea leaves. A few respondents did not know the cause of menses 164 165 suppression. Notably, menstrual suppression surprised the majority of participants, despite 166 knowing about it or having received counseling about it from providers. Findings revealed that menstrual suppression was perceived in two different ways with most 167 participants expressing positive attitudes, and a few expressed negative attitudes. The study 168 169 findings are as summarised in the following themes, (i) perceived causes of menstrual 170 suppression, (ii) positive attitudes towards menstrual suppression with continuous use of the NuvaRing, (iii) negative attitudes towards menstrual suppression with continuous use of the 171 NuvaRing and (iv) male sexual partners' perceptions on menstrual suppression. 172

174

175 Perceived causes of menstrual suppression

- 176 Concerns related to menstrual suppression were not only limited to NuvaRing, because majority
- 177 of the participants' perception on major causes of menses suppression included contraception use
- including depot-medroxyprogesterone acetate (DMPA), emergency contraceptive pills,
- intrauterine device (IUD), and combined contraceptive pills. Additionally, they mentioned that
- stress, sickness, blood donations, changes in diet and climate can result to menses suppression. A
- 181 few of the participants did not know the cause of menses suppression despite having received
- 182 counseling on the possibility of menses suppression with continuous use of NuvaRing by the
- 183 study staff.

184 *"We can say mostly it suppresses when one starts using family planning which affects*

hormones. The first one is Depo, the second is this one called jadelle. Those are the one
that I know mostly suppresses. Stress can cause that (suppression), sometimes change of
climate" (IDI 09)

188 *"When I had exams, I had stress and panic and menses didn't come the following day so*

189 *I knew stress can cause that (suppression). Yes, to others, it depends with one's*

190 *hormones.* " (IDI 07)

191 Positive attitudes towards menstrual suppression with continuous use of the NuvaRing

Some of the positive attitudes included ability to run daily activities uninterrupted, reduced
expenses on sanitary supplies, improved sexual experience and relationships, reduced menstrual
pain, blood loss, worries and odour as a result of menstruation especially those who experienced
heavy menses.

196	Most participants who experienced menstrual suppression liked that it resulted in reduction of
197	menstrual pain which enabled them to engage in their daily activities without pain unlike before.
198	"I feel okay that I don't have the pain. I felt happy because in the past, before I got
199	inserted the ring, I used to be moody, weak and with adnominal pain and heavy
200	bleeding" (IDI 06)
201	"I like staying without menses because you know it is stressful, maybe you are at work or
202	any other place and then you start having backache and abdominal pain; and you don't
203	have restrictions in movement" (IDI 01)
204	In addition, their self-esteem and comfort improved as they did not have worries and/or fears of
205	soiling their clothes and therefore their movement was not restricted like they used to experience,
206	before using NuvaRing, especially those who experienced heavy menses.
207	"I just feel comfortable. In the past before I joined this clinic (joining the study) I could
208	not wear a skirt, I had to wear a trouser so that I wear a pant and hot pant to hold but
209	now I only have a skirt and pant on and I am comfortable." (IDI 06)
210	Some participants liked menses suppression because it reduced blood loss and odour they
211	experienced during menses before the use of NuvaRing. They said menstruation reduced blood
212	levels, especially among people who experienced heavy menses. During menstruation, some
213	participants had an odor that made them feel uncomfortable around people, but suppression made
214	them to feel more comfortable and self-confident.
215	"Yes, he knows (menses suppression). He used to complain about the discharge because
216	it used to odour, so it got to a point that the discharge ended and he was happy, he even
217	told the doctor that the ring is good when we came here." (IDI 09)

218	Further, a few participants were satisfied with menstrual suppression, and expressed desire to								
219	purchase the NuvaRing after the study because it allowed them to save money by eliminating the								
220	need to purchase on sanitary supplies including sanitary towels, soap and water to maintain								
221	personal hygiene when on menses. They felt the much money spent on sanitary supplies would								
222	rather be spent on something else.								
223	"You do not buy sanitary towels (laughing). You know in our place we buy water, so you								
224	don't buy water often because you take a bath in the morning, afternoon and at night;								
225	you have to wash clothes and you have to buy soap. I will say that the ring is ok because I								
226	don't feel what I used to feel in the past and it has helped me as I saved money (laughing)								
227	it is ok with me." (IDI 06)								
228	"I am free (laughing)from the stress of buying sanitary towels, and I save and the								
229	money for buying something else." (IDI 07)								
230	Some participants experienced enhanced sexual satisfaction and relationships as their partners								
231	were happy because they could engage in sex whenever they wanted. Before suppression, some								
232	participants were uncomfortable engaging in sex during menses whenever their partners								
233	requested for it.								
234	"You know when I had menses, he was not happy but now when I don't have, he is								
235	enjoying it every day (laughing). " (IDI 01)								
236	A few participants were not surprised with suppression of their menses because they were aware								
237	of menstrual suppression since they had been informed by the study staff of the possibility with								
238	NuvaRing use. They also received the information before joining the study from health providers								
239	in different health facilities, as well as from peers and other women in the community. Further,								
	11 P a g e								

some participants reported that they had experienced menstrual suppression prior to joining thestudy.

242	"I was told I may, or I may not get menses so I waited knowing that I may or may not get
243	menses. I usually don't have a problem because when you have a man in the house is
244	when you fear." (IDI 15)
245	"I didn't do a thing because before using the ring I used to use depo which suppresses
246	menses, so I knew that." (IDI 18)
247	"Aah I had not messed so I was shocked because I didn't know what was happening, so
248	I thought it was the ring because when you are injected (depo) you miss menses. I just
249	waited, and when I was almost to come here but I got my menses." (IDI 11)

250 Negative attitudes towards menstrual suppression with continuous use of the NuvaRing

Negative attitudes included possibility of unintended pregnancies, health conditions such as cervical cancer and hormonal imbalances; this prompted anxiety and fear resulting to hospital check-ups, and home-based self-pregnancy testing. Some participants expressed surprise and anxiety with menstrual suppression despite having experienced menstrual suppression before NuvaRing use and having had prior counselling/ knowledge/information on the possibility of menses suppression with the continuous use of the NuvaRing from study staff, health providers, peers and women in the community.

All participants apart from one reported the fear of possibility of unintended pregnancy and
negative health consequences including infertility, hormonal imbalances, cancer, infections
among others. When participants missed their menses they developed anxiety, fears and worries

of the likelihood of them having conceived because they knew that they had engaged in
unprotected sex. This is because they felt that sometimes contraception might fail and end up
conceiving, especially given that NuvaRing was new to a few of the participants. Some of the
participants reported that they wondered what could have happened because they had not
engaged in sex.

- 266 "I thought I had become pregnant. That is the only thing that was disturbing me. I
 267 decided that the day I come here and get told that I am pregnant I will ask them why they
 268 inserted me the ring and it does not help me and tell them to take back their thing. I really
 269 felt bad because even when I was in the house, I used to feel I had a big problem
- 270 (pregnancy) ahead of me." (IDI 16)
- 271 "For now, I am used to, but there is a time I used to have stress. You cannot know, for
 272 example if I am with my husband I will not tell if the family planning has worked, or it
 273 has not worked so all the time there are fears of pregnancy." (IDI 07)

274 This resulted in participants visiting the study site and other health facilities for pregnancy tests 275 and general inquiry on the cause of suppression. Some participants said that they were afraid 276 because they did not know what was happening with their menses and/or their health and so they decided to visit the study site and health facilities for pregnancy test and consultation. A few 277 278 participants decided to buy pregnancy test kits to carry out personalized pregnancy tests. After negative pregnancy tests, both by the study staff and personalized tests, and confirmation from 279 280 the study staff that they did not have any health problem, some participants reported feeling comfortable, but a few participants said they always developed anxiety whenever they 281 experienced suppression. 282

283	"Aaah I had not messed (unprotected sex) so I was shocked because I didn't know
284	what was happening, so I thought it was the ring. I was not comfortablewhen I came
285	here and got explained to, I got comfortable". (IDI 11)
286	"Ok, I was wondering because I missed my menses the time, I expected so I wondered
287	and asked myself like could I be pregnant and yet I have a ring? I kept quiet but I went
288	and bought a test kit and found that I was ok, so I waited." (IDI 04)
289	"MmmhI was shocked a bit, but I said to myself that maybe they have delayed. I just
290	went for a check-up, I asked, and I was told that they have delayed. I came here and they
291	told me that I am ok." (IDI 02)
292	A few participants said that they did not like menstrual suppression since they did not know
293	when to expect their menses. They reported that they had to keep their sanitary towels in their
294	travelling bags so that they could easily access them if they received their menses unawares.
295	"I was ok but I used to plan myself well like I had sanitary towels with me always when I
296	am on journey because it can come when I am anywhere." (IDI 18)
297	"I feel bad and bored because sometimes you carry sanitary towels every day and it does
298	not come." (IDI 01)
299	These fears are informed by the community perception that if a woman does not get menses, then
300	there is a likelihood that she is pregnant if she engages in sex, has hormonal imbalance or a
301	health problem including infertility and that they are abnormal or bewitched and therefore they
302	should not get married. Additionally, they said that women experience menses suppression
303	usually develop big tummies/ bellies.

304 "...where I come from, we know that when one has menses you are not pregnant, and 305 some say that if you don't get menses then you can get like cancer." (IDI 01)

306 Male sexual partners' perceptions on menstrual suppression

The majority of the women reported that they did not disclose to their partners about their menstrual suppression because they are reserved discussing about their menses. However, 5 of the 18 women disclosed the use of NuvaRing and their menstrual suppression with their partners. One participant reported that her partner was supportive of the use of the NuvaRing because he did not like menses. A few participants said that their partners perceived menses suppression negatively because they believed it had negative effects on women's health and therefore said that the NuvaRing was not good.

- "He was happy because he also doesn't like it.....He knows I had planned (having
 contraception), and I came asked the doctor about it and I was told that missing menses
 is not bad because the ovaries are not there...so I explained to him so." (IDI 01)
- 317 *"He tells me that it (menstrual suppression) is caused by the things I use." (IDI 03)*

318 Discussion

Findings revealed that while some women naturally experienced menstrual suppression, others intentionally suppressed their menses, and some women induced it after suppression. Most participants associated menstrual suppression with contraception use, infertility, hormonal imbalance, stress, blood donations, dietary changes, and environmental changes. Similar to reports from other studies, some participants were aware of menses suppression and its causes before and after joining the study (9,13–18,20), while others were unaware despite receiving regular menstrual suppression counseling and the possibility of suppression with continued

NuvaRing use. These findings highlight participants' different levels of knowledge/awareness on
 menses suppression highlighting the significance and need for continued comprehensive
 counselling on matters menstrual health and suppression.

Findings revealed that while some participants expressed positive attitudes concerning menstrual 329 suppression with continued NuvaRing use, others had negative attitudes. These experiences and 330 attitudes are worth considering because they may influence the acceptability and use of an 331 332 intervention or product, in this case, NuvaRing. This finding is supported by existing literature (9,13-18,20) which show that different and varied needs, feelings, perceptions, beliefs, and 333 334 knowledge/awareness based on individual, interpersonal, societal, and cultural values, norms and beliefs. In this study, participants with positive experiences expressed acceptance and a desire to 335 336 continue using NuvaRing; however, those with negative attitudes had mixed emotions, with some expressing a desire to continue using NuvaRing but had fears of the unintended negative 337 338 consequences. These findings have been found with the use of other products as well, such as 339 contraception, other rings, and microbicides (13,13,18,22), showing the significance of end-user experiences in influencing the acceptability and use of an intervention or product, in this case, 340 341 the NuvaRing.

Menstrual suppression was well received among participants who were aware of it, which is supported by findings from other studies (13, 9,20). Similar to these studies, participants expressed positive experiences such as ability to engage in daily activities uninterrupted, enhanced marital relationships resulting from sexual satisfaction, reduction of expenses on sanitary supplies and blood loss. Although racial and regional/ geographical differences in menses suppression exist globally, other studies have also shown that women are positive with menses suppression since it supports women's quality of life through improving convenience,

and avoiding negative menses related outcomes such as heavy and prolonged menses, nausea,
bloating, fatigue and menstrual pain (13,19,20).

As other studies have shown, some participants reported negative experiences following menses 351 352 suppression with a preference in non-suppression (13,18,22). Similar to these studies, we found that menstrual suppression caused worry, fear, and anxiety about unintended pregnancies, among 353 354 negative health outcomes like infections, hormonal imbalances, and cancer. Existing literature demonstrate that contraceptives or ring users worry about future infertility and are uncertain 355 356 about birth control effectiveness hence preventing their use or result in discontinuation 357 (13,18,22). Although comprehensive counselling may not sufficient by itself, these concerns 358 illustrate how crucial it is to understand the user pregnancy intentions among other concerns to support designing and providing complete counselling messages on use and adherence to avoid 359 unintended consequences and support mental health (6,7,13–15,17,21,22). 360 Following pregnancy tests and a doctor's confirmation of no underlying health issues, the 361 362 majority of participants felt at ease. However, like other studies (13,16,18,19,22), a few participants had persistent fear and anxiety whenever they missed menses, and uncertainty about 363 when they expected menses disincentivizing them from NuvaRing use. These negative 364 experiences may be associated with existing literature (16) that the community regarded women 365 without menses as pregnant or infertile, abnormal, bewitched, or unhealthy. As indicated in other 366 367 studies, results from this study demonstrate varied participants' knowledge of potential side effects of continued NuvaRing use on menses suppression, highlighting the importance of end-368 user regular tailored comprehensive counseling of an interventions use including side effects. 369 370 This counseling should consider and align with individual and community levels of knowledge,

371	needs, feelings, perceptions and concerns to address potentially harmful or negative perceptions
372	that may influence an intervention or product acceptability, use and adherence (6,7,17,18,22).
373	Concerning male partners' awareness of menses suppression, most participants felt
374	uncomfortable discussing their menses and hence did not inform their partners about their
375	suppression (14,15), however, a few participants did. Male partners did not like NuvaRing,
376	except for one who disliked menses. These findings similar to other studies illustrate the major
377	role of male influence in acceptability and use of reproductive health interventions among
378	women, and the importance of male partner involvement in matters reproductive health to bridge
379	the gap between acceptability and actual use (6–9,13,18). Additionally, it shows the importance
380	of empowering women's self-agency in discussing and disclosing matters reproductive health
381	with their partners and male involvement in reproductive health matters to support and improve
382	acceptability and use of new reproductive health interventions among women (6-9).

383 Limitation

Studies with a large cohort and a representative sample of participants including male partners selected from various geographic locations and communities in Kenya may explain and enrich these findings since the interviews only included a small number of participants and hence may not be generalized.

388 Conclusion

Exploring women's experiences with continuous NuvaRing use in relation to menstrual changes helps develop an understanding of how menstrual suppression may influence their decisionmaking and preference for NuvaRing use and adherence. In this study, some participants preferred continued NuvaRing use owing to the benefits that improved women's quality of life resulting from suppression, while others preferred non-suppression due to perceived unintended

health outcomes and considered it abnormal, thus did not wish to use NuvaRing. In addition, 394 male partners did not like NuvaRing, except for one who disliked menses. These findings are 395 pertinent in informing the development, marketing, roll-out, education/ awareness creation, 396 designing tailored-comprehensive counselling for users during service delivery for future MPTs 397 product or intervention for HIV/ STIs and pregnancy prevention. Additionally, the results 398 399 highlight the significance of enhancing women's agency in discussions about reproductive health issues. Moreover, the study shows the importance of male involvement in reproductive health 400 matters because of their crucial role in influencing reproductive health interventions or product 401 402 use.

403 Informed Consent

All participants provided written informed consent to participate in the study. Women and men who were unable to read or write and expressed interest in the study were offered to have the consent read to them with a witness present. All the study materials were labelled using a unique identifier.

408 Ethical approval

409 All procedure performed in this study were in accordance with the ethical approval that was

410 obtained from Kenya Medical Research Institute's Scientific Review committee and Ethics

411 Review Board (SERU).

412 Acknowledgement

413 We thank participants who took part in the study and the study staff at the KEMRI-CCR,

414 (PHRD)Thika Project in Kenya for all of their hard work.

415 Authors Contribution

- NM, JM, and KN were involved in the study's conception, design, and funding. EC conducted
- the interviews, and two behavioral scientists (EC and NW) created a codebook based on the
- 418 interview guide topics. EC and NW coded and reviewed the coded transcripts under KN's
- supervision. EC compiled the report with manuscript review support from NW, CK, LO, SGM,
- 420 KWW, NM, JM, and KN. The manuscript was submitted by EC.

421 Funding

- 422 The study was funded by the National Institutes of Health_ National Institute of Child Health
- and Human Development (NIH-NICHD) award, grant number R01HD077872.

424 **Conflict of Interest Declaration**

425 The authors declare no competing interests.

426

427

429 **References**

- 430 1. UNAIDS data 2021 [Internet]. [cited 2022 Aug 15]. Available from:
- 431 https://www.unaids.org/en/resources/documents/2021/2021_unaids_data
- 432 2. Global HIV & AIDS statistics Fact sheet [Internet]. [cited 2022 Aug 15]. Available from:
- 433 https://www.unaids.org/en/resources/fact-sheet
- 434 3. Kenya's National HIV Survey Shows Progress Towards Control of the Epidemic. Nairobi,
- 435 20th February 2020 MINISTRY OF HEALTH [Internet]. [cited 2022 Aug 15]. Available
- 436 from: https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towards-control-
- 437 of-the-epidemic-nairobi-20th-february-2020/
- 4. Kenya Preliminary Report 2018 [Internet]. PHIA Project. [cited 2022 Aug 15]. Available
 from: https://phia.icap.columbia.edu/kenya-preliminary-report/
- 5. WORLD AIDS DAY REPORT 2020.pdf | Powered by Box [Internet]. [cited 2022 Aug 15].
- 441 Available from: https://app.box.com/s/kb1f0tkbjhlcn2a610too8vlpizxqla8
- 442 6. Montgomery ET, Roberts ST, Reddy K, Tolley E, Hartmann M, Wilson E, et al. Integration

of a Relationship-focused Counseling Intervention with Delivery of the Dapivirine Ring for

- 444 HIV Prevention to Women in Johannesburg: Results of the CHARISMA Pilot Study. AIDS
- 445 Behav. 2022 Mar 1;26(3):752–63.
- 446 7. Montgomery ET, Katz AWK, Duby Z, Mansoor LE, Morar NS, Naidoo K, et al. Men's
- 447 Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and
- 448 Zimbabwe. AIDS Behav. 2021 Jun 1;25(6):1890–900.

449	8.	Roberts ST, Nair G, Baeten JM, Palanee-Philips T, Schwartz K, Reddy K, et al. Impact of
450		Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a
451		Phase III HIV Prevention Trial. AIDS Behav. 2020 May 1;24(5):1432–42.
452	9.	Pleasants E, Tauya T, Reddy K, Mirembe BG, Woeber K, Palanee-Phillips T, et al.
453		Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN
454		020/ASPIRE Trial. AIDS Behav. 2020 Mar 1;24(3):866-80.
455	10.	Young Holt B, Turpin JA, Romano J. Multipurpose Prevention Technologies: Opportunities
456		and Challenges to Ensure Advancement of the Most Promising MPTs. Frontiers in
457		Reproductive Health [Internet]. 2021 [cited 2022 Aug 15];3. Available from:
458		https://www.frontiersin.org/articles/10.3389/frph.2021.704841
459	11.	Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, et al. Bacterial
460		Vaginosis Associated with Increased Risk of Female-to-Male HIV-1 Transmission: A
461		Prospective Cohort Analysis among African Couples. PLOS Medicine. 2012 Jun
462		26;9(6):e1001251.
463	12.	Bayigga L, Kateete DP, Anderson DJ, Sekikubo M, Nakanjako D. Diversity of vaginal
464		microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention.
465		American Journal of Obstetrics and Gynecology. 2019 Feb 1;220(2):155-66.
466	13.	Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women's
467		responses to contraceptive-induced menstrual bleeding changes. Reproductive Health. 2018
468		Jun 26;15(1):114.

469	14. Duby Z, Katz A, Musara P, Nabukeera J, Zimba CC, Woeber K, et al. "The state of mind
470	tells me it's dirty": menstrual shame amongst women using a vaginal ring in Sub Saharan
471	Africa. Women Health. 2020 Jan;60(1):72–86.
472	15. Duby Z, Katz AWK, Browne EN, Mutero P, Etima J, Zimba CC, et al. Hygiene, Blood
473	Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring
474	During Menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2020
475	Feb;24(2):617–28.
476	16. Ghiasl A. The effect of gender-role orientation on attitudes towards menstruation in a sample
477	of female university students. J Turk Ger Gynecol Assoc. 2019 Sep;20(3):138-41.
478	17. Laher F, Todd CS, Stibich MA, Phofa R, Behane X, Mohapi L, et al. Role of menstruation in
479	contraceptive choice among HIV-infected women in Soweto, South Africa. Contraception.
480	2010 Jun;81(6):547–51.
481	18. McLellan-Lemal E, Ondeng'e K, Gust D, Desai M, Otieno F, Madiega P, et al.
482	Contraceptive vaginal ring experiences among women and men in Kisumu, Kenya: A
483	qualitative study. Front Womens Health. 2017 Mar;2(1):10.15761/FWH.1000122.
484	19. Hillard PA. Menstrual suppression: current perspectives. Int J Womens Health. 2014 Jun
485	23;6:631–7.
486	20. Trego LL, Jordan PJ. Military Women's Attitudes Toward Menstruation and Menstrual
487	Suppression in Relation to the Deployed Environment: Development and Testing of the
488	MWATMS-9 (Short Form). Women's Health Issues. 2010 Jul 1;20(4):287–93.

489	21.	Todd CS,	Stibich MA.	Laher F.	Malta MS.	Bastos FI.	Imbuki K.	et al.	Influence	of culture
-----	-----	----------	-------------	----------	-----------	------------	-----------	--------	-----------	------------

490 on contraceptive utilization among HIV-positive women in Brazil, Kenya, and South Africa.

- 492 22. Leslie J, Kiweewa F, Palanee-Phillips T, Bunge K, Mhlanga F, Kamira B, et al. Experiences
- 493 with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-
- 494 Saharan Africa. BMC Women's Health. 2021 Apr 23;21(1):175.

⁴⁹¹ AIDS Behav. 2011 Feb;15(2):454–68.